## 4 Conclusions  
We developed a simultaneous analysis method for selected compounds **1-18** that enables the quality assessment of CSBPT based on a common and widely-used HPLC-PDA system. The developed assay was validated by evaluating linearity, LOD, LOQ, recovery, and precision, and it was successfully applied to the analysis of CSBPT samples. This HPLC-PDA analytical assay can be used as a framework to obtain basic data for quality assessment of CSBPT and other traditional Korean medicines in the future.  
The following are available online at [[https://www.mdpi.com/2076-341/11/1/14/s1](https://www.mdpi.com/2076-341/11/1/14/s1)]([https://www.mdpi.com/2076-341/11/1/14/s1](https://www.mdpi.com/2076-341/11/1/14/s1)), Figure S1: HPLC chromatogram of constituent herbal medicine and its major components. A: S. _divariate_; B: A. _dahurica_; C: F. _viridissima_; D: P. _grandiform_; E: S. _baiaclensis_; F: C. _officiale_; G: S. _tenuifolia_; H: G. _jasmitooides_; I: C. _japonica_; J: C. _aurantum_; K: M. _aroensis_; and L: G. _uralensis_, Figure S2: HPLC chromatograms of the standard solution (A) and 70% methanol extract of CSBPT sample (B). Gardenoside (**1**), geniposide (**2**), coptisine chloride (**3**), _prim_-O-glucosylcimifugin (**4**), berberine chloride (**5**), palmatine chloride (**6**), liquiiritin apioside (**7**), liquiiritin (**8**), ferulic acid (**9**), nariritin (**10**), 5-O-methylcismamiside (**11**), naringin (**12**), hesperidin (**13**), neohesperidin (**14**), arctigenin (**15**), platycodin D2 (**16**), baialein (**17**), platycodin D (**18**), liquiirigenin (**19**), oxypeuedanin hydrate (**20**), wogonoside (**21**), baialein (**22**), menthole (**23**), arcitin (**24**), glycyrrhizin (**25**), wogonin (**26**), oxypeucedanin (**27**), pulgeone (**28**), menthone (**29**), imperatoin (**30**), isolimeratorin (**31**), Figure S3: Chemical structures of compounds **1-18** in CSBPT, Table S1: Composition of CSBPT, Table S2: Chromatographic conditions for simultaneous quantification of compounds **1-18** in CSBPT, Table S3: System suitability of compounds **1-18**.  
Conceptualization: C.-S.S. and H.-K.S.; performing experiments and analyzing data: C.-S.S.; writing--original draft preparation: C.-S.S.; funding acquisition: H.-K.S. All authors have read and agreed to the published version of the manuscript.  
This research was supported by a grant from the Korea Institute of Oriental Medicine (No. KSN2013310).  
The authors have declared no conflict of interest.  
\begin{table}
\begin{tabular}{c c c c c c c} \hline \hline \multirow{2}{*}{**Analyte**} & \multicolumn{4}{c}{**Batch No.**} \\ \cline{2-7}  & \multicolumn{2}{c}{**I**} & \multicolumn{2}{c}{**II**} & \multicolumn{2}{c}{**III**} \\ \cline{2-7}  & \multicolumn{2}{c}{**Mean (mg/g) \(\pm\)**} & \multirow{2}{*}{**RSD (\%)**} & \multicolumn{2}{c}{**Mean (mg/g) \(\pm\)**} & \multirow{2}{*}{**RSD (\%)**} & \multicolumn{2}{c}{**Mean (mg/g) \(\pm\)**} & \multirow{2}{*}{**RSD (\%)**} \\  & \multicolumn{2}{c}{**SD (\(\times 10^{-2}\))**} & & & & & \\ \hline
**1** & 5.33 \(\pm\) 1.02 & 0.19 & 5.35 \(\pm\) 4.59 & 0.86 & 5.41 \(\pm\) 3.41 & 0.63 \\
**2** & 0.70 \(\pm\) 0.45 & 0.63 & 0.75 \(\pm\) 0.31 & 0.41 & 0.71 \(\pm\) 0.